# Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

> **NCT05418088** · PHASE1 · RECRUITING · sponsor: **Sumithira Vasu** · enrollment: 54 (estimated)

## Conditions studied

- Recurrent Acute Lymphoblastic Leukemia
- Recurrent B Acute Lymphoblastic Leukemia
- Recurrent B-Cell Prolymphocytic Leukemia
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent High Grade B-Cell Lymphoma
- Recurrent Indolent Non-Hodgkin Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Transformed Chronic Lymphocytic Leukemia
- Refractory Acute Lymphoblastic Leukemia
- Refractory B Acute Lymphoblastic Leukemia
- Refractory B-Cell Prolymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Refractory High Grade B-Cell Lymphoma
- Refractory Indolent Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Transformed Chronic Lymphocytic Leukemia
- Refactory Childhood Acute Lymphoblastic Leukemia
- Refractory Childhood Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Anti-CD19/CD20/CD22 CAR T-Cells
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine Phosphate
- **PROCEDURE:** Echocardiography
- **PROCEDURE:** Multigated Acquisition Scan
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Pheresis
- **PROCEDURE:** Bone Marrow Aspiration and Biopsy
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT05418088
- **Lead sponsor:** Sumithira Vasu
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-30
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-07-31
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05418088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05418088, "Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05418088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*